Clinical Brief: Prevention and Treatment of Influenza in High-Risk Patients with Cardiometabolic Comorbidities
This enduring clinical brief was developed from a primetime symposium at the 2021 CMHC Annual Congress. Moderated by Dr. Gregory Poland, the symposium reviewed the latest literature on the epidemiology, prevention, diagnosis, and treatment for influenza.
Category
  • CMHC
Format
  • Monograph
Credits
  • ABIM MOC and AMA PRA Category 1 Credit
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Clinical Brief: Challenges and Advances in Diabetic Kidney Disease
This enduring clinical brief was developed from a primetime symposium at the 2021 CMHC Annual Congress. Moderated by Dr. Bakris, the symposium highlighted the importance of and the challenges in managing renal disease in patients with diabetes.
Category
  • CMHC
Format
  • Monograph
Credits
  • ABIM MOC and AMA PRA Category 1 Credit
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Clinical Brief: Should Diabetes Management be More Adipose-centric?
The co-occurrence of diabetes and obesity is now commonly termed “diabesity”- a new worldwide epidemic.
Category
  • CMHC
Format
  • Monograph
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Clinical Brief: The Disproportionate Burden of ATTR-CM In African Americans
ATTR cardiac amyloidosis (ATTR-CM) is a complex disease that remains challenging to diagnose and treat, and disproportionally affects African American patients.
Category
  • CMHC
Format
  • Monograph
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Digital Pathway - Changing The Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, ‘High-Intensity Lipid Lowering Therapy’ to Improve Outcomes
Patients with a recent myocardial infarction (MI) are at very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events, however, targeted LDL-C goal achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal.
Category
  • CMHC
Format
  • Monograph
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Digital Pathway - Bridging the Frontiers of Care in Patients with T2D and CKD: Interpreting the Data with Novel MR Antagonists to Improve Cardiorenal Outcomes
Recent advances in the understanding of CKD progression in patients with type 2 diabetes have opened up new avenues of treatment that can potentially address some of the challenges and decrease cardiorenal risk in these patients.
Category
  • CMHC
Format
  • Monograph
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Digital Pathway - The Evolving Landscape of LDL-C Reduction in High Risk Patients: Optimizing Combination Therapy to Reduce ASCVD Risk
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events.
Category
  • CMHC
Format
  • Monograph
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation